Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Akoya Biosciences (NASDAQ:AKYA) over the past three months, with recent price targets showing a downward trend. The average 12-month price target is now $6.5, down from $9.75. Financial performance indicators reveal challenges, including a decline in revenue and below-average returns on equity and assets.
June 03, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akoya Biosciences has received mixed ratings from analysts, with a recent downward trend in price targets. Financial performance indicators show challenges, including a decline in revenue and below-average returns on equity and assets.
The mixed analyst ratings and the significant reduction in price targets indicate a bearish sentiment. Additionally, the company's financial performance, including a decline in revenue and below-average returns, suggests potential short-term challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100